(Boursier.com) — Abivax SA, a Phase 3 clinical-stage biotechnology company developing immune-modulating drugs to treat patients with chronic inflammatory diseases, today announced that its leadership team will attend the 41st JP Morgan Annual Healthcare Conference and LifeSci Partners’ 12th Annual Corporate Access Event to be held January 9-12, 2023 in San Francisco, USA.
During these conferences, the Abivax management team will be available for one-on-one meetings in San Francisco. Investors and other interested parties can request a meeting through the LifeSci CAE 2023 Registration platform.
©2022 Boursier.com